Pat Cotroneo
Pat Cotroneo is a seasoned life sciences financial executive who spent over two decades at FibroGen, Inc. (now Kyntra Bio), serving as Chief Financial Officer from 2008 to 2021. During his tenure, he guided FibroGen through two defining transformations: its landmark 2014 IPO - the largest biotech public offering in 12 years - and its evolution into a commercial-stage company with the launch of roxadustat in China in 2019. With 25+ years of senior financial leadership in life sciences, Cotroneo built his career at Deloitte & Touche, SyStemix (a Novartis subsidiary), and ultimately FibroGen, where he oversaw finance, accounting, human resources, and information technology before transitioning to Executive Advisor to the CEO.
cfofibrogenkyntra-biobiotechnologylife-sciencessan-francisco